ArticleEuropean journal of clinical investigation2023
Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy.
Article in European journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Excess mortality in Mainland China after the end of the Zero COVID policy: A systematic review.Epidemiology and infection · 2026Pooled it
- The role of social media on COVID-19 preventive behaviors worldwide, systematic review.PloS one · 2024Pooled it
- Gastrointestinal Symptoms and Abnormal Liver Biochemistry in Patients with COVID-19 Pneumonia Admitted to the Department of Gastroenterology After Ending Zero-COVID Policy in China.Advances in therapy · 2026Article
- Desensitization reduces some COVID-19-associated symptoms in minors with allergic rhinitis.BMC infectious diseases · 2025Article
- Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.Bone marrow transplantation · 2025Article
- Article
- Article
- Hybrid ARIMA-LSTM for COVID-19 forecasting: a comparative AI modeling study.PeerJ. Computer science · 2025Article
- Healthcare professionals' perceptions of system preparedness during public health emergencies: a path analysis of mental health impacts.Frontiers in public health · 2025Article
- Sex- and age-specific differences in excess mortality in China during the COVID-19 pandemic: a study based on official vital statistics data.Frontiers in epidemiology · 2025Article
- The spatiotemporal analysis of SARS-CoV-2 transmission in China since the termination of the dynamic zero-COVID policy.Virologica Sinica · 2024Article
- Post-Pandemic Epidemiology of Respiratory Infections among Pediatric Inpatients in a Tertiary Hospital in Shanghai, China.Children (Basel, Switzerland) · 2024Article
- Prevalence and factors influencing long COVID among primary healthcare workers after epidemic control policy adjustment in Jiangsu, China.BMC infectious diseases · 2024Article
- Analysis of health service utilization and influencing factors due to COVID-19 in Beijing: a large cross-sectional survey.Health research policy and systems · 2024Article
- Severe pneumonia with co-infection of H5N1 and SARS-CoV-2: a case report.BMC infectious diseases · 2024Article
- COVID-19 Omicron variant infection has minimal impact on maternal and neonatal outcomes: A cross-sectional cohort study.Nursing open · 2024Article
- Increase in complicated upper respiratory tract infection in children during the 2022/2023 winter season-a post coronavirus disease 2019 effect?Pediatric radiology · 2024Article
- Multicultural personality traits of Chinese university students and their effects on the psychological adjustment in the aftermath of COVID-19 in Shanghai: a scale validation.Frontiers in psychiatry · 2024Article
- The association of calligraphy activities with peace of mind, stress self-management, and perceived health status in older adults.Frontiers in psychology · 2024Article
- Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID-19: A Propensity Score-Matched Analysis.Infection and drug resistance · 2024Article
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
backgroundChina witnessed a surge of Omicron infections after abandoning 'zero COVID' strategies on 7 December 2022. The authorities report very sparse deaths based on very restricted criteria, but massive deaths are speculated.
methodsWe aimed to estimate the COVID-19 fatalities in Mainland China until summer 2023 using the experiences of Hong Kong and of South Korea in 2022 as prototypes. Both these locations experienced massive Omicron waves after having had very few SARS-CoV-2 infections during 2020-2021. We estimated age-stratified infection fatality rates (IFRs) in Hong Kong and South Korea during 2022 and extrapolated to the population age structure of Mainland China. We also accounted separately for deaths of residents in long-term care facilities in both Hong Kong and South Korea.
resultsInfection fatality rate estimates in non-elderly strata were modestly higher in Hong Kong than South Korea and projected 987,455 and 619,549 maximal COVID-19 deaths respectively, if the entire China population were infected. Expected COVID-19 deaths in Mainland China until summer 2023 ranged from 49,962 to 691,219 assuming 25-70% of the non-elderly population being infected and variable protection of elderly (from none to three-quarter reduction in fatalities). The main analysis (45% of non-elderly population infected and fatality impact among elderly reduced by half) estimated 152,886-249,094 COVID-19 deaths until summer 2023. Large uncertainties exist regarding potential changes in dominant variant, health system strain and impact on non-COVID-19 deaths.
conclusionsThe most critical factor that can affect total COVID-19 fatalities in China is the extent to which the elderly can be protected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.